{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:50:22Z","timestamp":1778640622486,"version":"3.51.4"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Sirolimus (mTOR inhibitor) is proven to be effective in children with congenital hyperinsulinism (CHI). Studies in animals suggest that sirolimus may have diabetogenic actions. However, its role in precipitating diabetes mellitus (DM) in children with CHI has not been reported.<\/jats:p>\n <\/jats:sec>\n \n Case presentation:<\/jats:title>\n \n A 16-year-old female with CHI due to a dominant\n ABCC8<\/jats:italic>\n gene mutation was switched from diazoxide therapy to sirolimus, due to the hypertrichosis side effect of diazoxide. She developed facial cellulitis that was treated with clarithromycin and a month later, once the infection was resolved, she was found to have persistent hyperglycaemia, and was diagnosed with DM. She was unresponsive to oral sulfonylurea therapy and is currently managed with metformin. Her mother, who had the same\n ABCC8<\/jats:italic>\n mutation, developed DM at her 30s.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n Patients with dominant\n ABCC8<\/jats:italic>\n gene mutations are prone to DM in adulthood, but Sirolimus therapy might increase the risk of developing diabetes at an early age, as this case illustrates.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2017-0148","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T06:01:39Z","timestamp":1507269699000},"page":"1219-1222","source":"Crossref","is-referenced-by-count":11,"title":["Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant\n ABCC8<\/i>\n mutation"],"prefix":"10.1515","volume":"30","author":[{"given":"Antonia","family":"Dastamani","sequence":"first","affiliation":[{"name":"Endocrinology Department , Great Ormond Street Hospital for Children NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"G\u00fcemes","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Great Ormond Street Hospital for Children NHS Trust , London , UK"},{"name":"Genetics and Genomic Medicine Programme, Genetics and Epigenetics in Health and Disease Section, Institute of Child Health , University College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Paediatrics , Portsmouth Hospitals NHS Trust , Portsmouth , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Shah","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Great Ormond Street Hospital for Children NHS Trust , London , UK"},{"name":"Genetics and Genomic Medicine Programme, Genetics and Epigenetics in Health and Disease Section, Institute of Child Health , University College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Hussain","sequence":"additional","affiliation":[{"name":"Division Chief \u2013 Endocrinology Vice Chair for Research, Department of Pediatric Medicine , Sidra Medical and Research Center , OPC, C6-337, PO Box 26999 , Doha , Qatar , Phone: +974-4003-7608\/974-30322007"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"key":"2026030709132405235_j_jpem-2017-0148_ref_001_w2aab3b7b8b1b6b1ab1b4b1Aa","doi-asserted-by":"crossref","unstructured":"Senniappan S, Alexandrescu S, Tatevian N, Shah P, Arya V, et al. Sirolimus therapy in infants with severe hyperinsulinaemic hypoglycaemia. N Engl J Med 2014;370:1131\u20137.10.1056\/NEJMoa1310967","DOI":"10.1056\/NEJMoa1310967"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_002_w2aab3b7b8b1b6b1ab1b4b2Aa","doi-asserted-by":"crossref","unstructured":"M\u00e9der \u00dc, Bokodi G, Balogh L, K\u00f6rner A, Szab\u00f3 M, et al. Severe hyperinsulinemic hypoglycemia in a neonate: response to sirolimus therapy. Pediatr 2015;136:1369\u201372.10.1542\/peds.2014-4200","DOI":"10.1542\/peds.2014-4200"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_003_w2aab3b7b8b1b6b1ab1b4b3Aa","doi-asserted-by":"crossref","unstructured":"Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411\u20138.10.1681\/ASN.200711120218385422","DOI":"10.1681\/ASN.2007111202"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_004_w2aab3b7b8b1b6b1ab1b4b4Aa","doi-asserted-by":"crossref","unstructured":"Rovira J, Ram\u00edrez-Bajo MJ, Banon-Maneus E, Moya-Rull D, Ventura-Aguiar P, et al. mTOR inhibition: reduced insulin secretion and sensitivity in a rat model of metabolic syndrome. Transplant Direct 2016;2:65.","DOI":"10.1097\/TXD.0000000000000576"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_005_w2aab3b7b8b1b6b1ab1b4b5Aa","doi-asserted-by":"crossref","unstructured":"Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877\u201386.1859692410.1172\/JCI35414","DOI":"10.1172\/JCI35414"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_006_w2aab3b7b8b1b6b1ab1b4b6Aa","doi-asserted-by":"crossref","unstructured":"Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8\/KCNJ11 mutations. Diabetologia 2011;54:2575\u201383.2167417910.1007\/s00125-011-2207-4","DOI":"10.1007\/s00125-011-2207-4"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_007_w2aab3b7b8b1b6b1ab1b4b7Aa","doi-asserted-by":"crossref","unstructured":"Senniappan S, Shanti B, James C, Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. J Inherit Metab Dis 2012;35:589\u2013601.10.1007\/s10545-011-9441-222231386","DOI":"10.1007\/s10545-011-9441-2"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_008_w2aab3b7b8b1b6b1ab1b4b8Aa","doi-asserted-by":"crossref","unstructured":"Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, et al. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301\u20137.1255986510.1016\/S0140-6736(03)12325-2","DOI":"10.1016\/S0140-6736(03)12325-2"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_009_w2aab3b7b8b1b6b1ab1b4b9Aa","doi-asserted-by":"crossref","unstructured":"Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko H-L, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 2000;106; 897\u2013906.10.1172\/JCI980411018078","DOI":"10.1172\/JCI9804"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_010_w2aab3b7b8b1b6b1ab1b4c10Aa","doi-asserted-by":"crossref","unstructured":"Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, et al. Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 2003;52:2403\u201310.1294178210.2337\/diabetes.52.9.2403","DOI":"10.2337\/diabetes.52.9.2403"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_011_w2aab3b7b8b1b6b1ab1b4c11Aa","doi-asserted-by":"crossref","unstructured":"Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009;4:135\u201342.10.1007\/s11523-009-0107-z19381454","DOI":"10.1007\/s11523-009-0107-z"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_012_w2aab3b7b8b1b6b1ab1b4c12Aa","doi-asserted-by":"crossref","unstructured":"Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236\u201344.1680740510.1681\/ASN.2006030196","DOI":"10.1681\/ASN.2006030196"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_013_w2aab3b7b8b1b6b1ab1b4c13Aa","doi-asserted-by":"crossref","unstructured":"Pavlakis M, Goldfarb-Rumyantzev AS. Diabetes after transplantation and sirolimus: what\u2019s the connection? J Am Soc Nephrol 2008;19:1255\u20136.1857963610.1681\/ASN.2008050474","DOI":"10.1681\/ASN.2008050474"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_014_w2aab3b7b8b1b6b1ab1b4c14Aa","doi-asserted-by":"crossref","unstructured":"Berg CE, Lavan BE, Rondinone CM. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 2002;293:1021\u20137.1205176210.1016\/S0006-291X(02)00333-9","DOI":"10.1016\/S0006-291X(02)00333-9"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_015_w2aab3b7b8b1b6b1ab1b4c15Aa","doi-asserted-by":"crossref","unstructured":"Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945\u201395.10.2337\/db07-0922","DOI":"10.2337\/db07-0922"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_016_w2aab3b7b8b1b6b1ab1b4c16Aa","doi-asserted-by":"crossref","unstructured":"Teutonico A, Schena P, Di Paolo S. Glucose metabolism in renal transplant recipients. Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128\u201335.10.1681\/ASN.200505048716107580","DOI":"10.1681\/ASN.2005050487"},{"key":"2026030709132405235_j_jpem-2017-0148_ref_017_w2aab3b7b8b1b6b1ab1b4c17Aa","doi-asserted-by":"crossref","unstructured":"Capone D, Palmiero G, Gentile A, Basile V, Fedetico S, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr Drug Metab 2007;8:379\u201381.1750422510.2174\/138920007780655405","DOI":"10.2174\/138920007780655405"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2017.30.issue-11\/jpem-2017-0148\/jpem-2017-0148.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2017-0148\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2017-0148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:13:29Z","timestamp":1772874809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2017-0148\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,6]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,10,6]]},"published-print":{"date-parts":[[2017,10,26]]}},"alternative-id":["10.1515\/jpem-2017-0148"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2017-0148","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10,6]]}}}